Edition:
United States

Neurosearch A/S (NEUR.CO)

NEUR.CO on Copenhagen Stock Exchange

4.82DKK
23 Feb 2018
Change (% chg)

kr.-0.03 (-0.62%)
Prev Close
kr.4.85
Open
kr.4.66
Day's High
kr.4.90
Day's Low
kr.4.66
Volume
21,142
Avg. Vol
58,829
52-wk High
kr.5.20
52-wk Low
kr.3.04

Chart for

About

Neurosearch A/S (NEUR) is Denmark-based biopharmaceutical company. It specializes in the research, development and sale of drug candidates. The Company’s portfolio comprises three products: Tesofensine, a drug used in obesity, which works as a monoamine reuptake inhibitor (MRI); Seridopidine, which is applied in central nervous... (more)
No analyst recommendations are available for .

Overall

Beta: 0.10
Market Cap(Mil.): kr.118.35
Shares Outstanding(Mil.): 24.55
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Neurosearch A/S FY Operating Loss Down to Dkk ‍1.0​ Million

* FY OPERATING LOSS DKK ‍1.0​ MILLION VERSUS LOSS DKK 6.3 MILLION YEAR AGO

Feb 09 2018

BRIEF-Neurosearch Contemplates Divestiture Of The Company

* ‍IS NOW AT A STAGE OF ITS RESOLUTION PLAN AT WHICH IT INTENDS TO EXPLORE POSSIBILITY OF DIVESTING COMPANY DURING COMING MONTHS​

Dec 05 2017

BRIEF-NeuroSearch upgrades its guidance for 2017

* ‍UPGRADES 2017 GUIDANCE FROM AN OPERATING LOSS OF DKK 2.3-3.3 MILLION TO AN OPERATION LOSS OF ABOUT DKK 1 MILLION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 17 2017

Earnings vs. Estimates

No consensus analysis data available.